1Hiigle T,Schuetz P,DaikeIer T,et al.Late-onset systemic sclerosis-a systematic sysvey of the EULAR scleroderma trials and research group database[J].Rheumatology(Oxford),2011,50(1):161-165.
3Alba MA,Velasco C,Simeon CP,et al.Early-versus late-onset systemic sclerosis:differences in clinical presentation and outcome in 1037 Patients[J],Medicine(Baltimore),2014,93(2):73-81.
4Alamanos Y,Tsifetaki N,Voulgari PV,et al.Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002[J].Semin Arthritis Rheum,2005,34(5):714-720.
5Czirjak L,Kiss CG,Lovei C,et al.Survey of Raynaud,s phenomenon and systemic sclerosis based on a representative study of 10000 south-Transdanubian Hungarian inhabitants[J].CIin Exp Rheumatol,2005,23(6):801-808.
6Mayes MD,Lacey JV Jr,Beebe-Dimmer J,et al.Prevalence,incidence,survival,and disease characteristics of systemic sclerosis in a large US population[J].Arthritis Rheum,2003,48C8):2246-2255.
7Roberts-Thomson PJ,Jones M,Hakendorf P,et al.Scleroderma in South Australia:epidemiological observations of possible pathogenic significance[J].Intern Med J,2001,31(4):220-229.
8Steen VD,Oddis CV,Conte CG,et al.Incidence of systemic sclerosis in Allegheny County,Pennsylvania.A twenty-year study of hospital-diagnosed cases,1963-1982[J].Arthritis Rheum,1997,40(3):441-445.
9Laing TJ,Gillespie BW,Toth MB,et al.Racial differences in scleroderma among women in Michigan[J].Arthritis Rheum,1997,40(4):734-742.
1Miwa K,Matsubara T,Uno Y,et al.Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome.Int Heart J,2007,48 (3):417-422.
2Nakae R,Idei M,Kumano K,et al.Intracranial aneurysms in patients with CREST syndrome.Neurol Med Chir(Tokyo),2009,49(9):402-406.
3Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese pa- tients with systemic sclerosis. Arthritis Rheum, 1994, 37 ( 1 ) : 75-83.
4Walker UA, Tyndall A, Czirjok L, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma TriMs and Research (EUSTAR) group data- base. Ann Rheum Dis, 2009, 68(6) : 856-862.
5Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase Ⅲ in systemic sclerosis. Ann Intern Med, 1993, 119(10) : 1005-1013.
6Cavazzana I, Angela C, Paolo A, et al. Anti-RNA polymerase Ⅲ antibodies : a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev, 2009, 8 (7) : 580-584.
7Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther, 2003, 5 (2) : 80-93.
8Grassegger A, Pohla-Gubo G, Frauscher M, et al. Autoantibodies in systemic sclerosis (scleroderma) : clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr, 2008, 158(1-2) : 19-28.
9Gussin HA, Ignat GP, Varga J, et al. Anti-topoisomerase Ⅰ ( anti- Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum, 2001, 44(2) : 376-383.
10Cepeda E J, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curt Opin Rheumatol, 2004, 16(6) : 723-732.
